Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 151 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Medication safety review Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Comprehensive Police Fatigue Management Program

NCT00246051
View directory record Official record
Conditions
Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions
Sleep Hygiene Education, Expert-Led Sleep Disorders Screening and Treatment, Online Sleep Disorders Screening
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Sep 5, 2026, 3:02 AM EDT
Suspended Phase 1Phase 2 Interventional

Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease

NCT04771416
View directory record Official record
Conditions
Leukodystrophy, Globoid Cell
Interventions
PBKR03
Biological
Lead sponsor
Gemma Biotherapeutics
Industry
Eligibility
1 Month to 9 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 5, 2026, 3:02 AM EDT
Active, not recruiting Not applicable Interventional

Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolescents With Anxiety and OCD

NCT07024758
View directory record Official record
Conditions
Obsessive Compulsive Disorder (OCD), Anxiety Disorder of Childhood or Adolescence, Social Anxiety Disorder of Childhood, Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder, Panic Disorder, Panic Attacks, Panic Disorder (With or Without Agoraphobia), Phobia, Specific
Interventions
Parent Coached Exposure Therapy, Family Based, Internet-Based Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 5, 2026, 3:02 AM EDT
Withdrawn Phase 2 Interventional

Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

NCT04350450
View directory record Official record
Conditions
COVID, Coronavirus, COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Danavorexton in Anesthetized Adults

NCT05025397
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 5, 2026, 3:02 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

NCT05431088
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
46
States / cities
Mobile, Alabama • Hartford, Connecticut • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 5, 2026, 3:02 AM EDT
Terminated Phase 1 Interventional Results available

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumor
Interventions
KZR-261
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 5, 2026, 3:02 AM EDT
Withdrawn Not applicable Interventional

WellStart Reboot Study

NCT03731533
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
WellStart
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Not applicable Interventional Results available

Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp

NCT01930539
View directory record Official record
Conditions
Vitamin D Deficiency, Short Bowel Syndrome
Interventions
Ultraviolet B lamp
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Hospital-to-Home Care Transitions for High-risk Younger Adult Patients

NCT02532296
View directory record Official record
Conditions
Patient Discharge
Interventions
Transition Coach (TC), Control
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 60 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 5, 2026, 3:02 AM EDT
Not listed Phase 1Phase 2 Interventional

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

NCT04669587
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
ZB716, Palbociclib
Drug
Lead sponsor
EnhancedBio USA Inc.
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 5, 2026, 3:02 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Partnering With Patients for Improving Medication Safety During Transitions of Care: Implications for Work System Design

NCT03544034
View directory record Official record
Conditions
Patient Safety, Adverse Drug Event
Interventions
HomeTeam Toolkit
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

NCT02603120
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
61
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 2 Interventional

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

NCT01455090
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-650032, BMS-790052, BMS-791325, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

NCT02631876
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
Interventions
Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
53
States / cities
Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses

NCT02254993
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Kalispell, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 5, 2026, 3:02 AM EDT
Recruiting No phase listed Observational

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

NCT06274788
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Interventions
Omegaven® (fish oil triglycerides) Injectable Emulsion
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
1 Day to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Fountain Valley, California • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Not applicable Interventional

Sleep Quality in High School Students With Asthma - II

NCT03329066
View directory record Official record
Conditions
Asthma, Sleep, Asthma in Children
Interventions
MAST - Managing Asthma & Sleep in Teens, ASMA - Asthma Self-Management for Adol, Information & Referral Control Group
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

NCT03482453
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-788, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

NCT06503679
View directory record Official record
Conditions
Healthy
Interventions
LY4100511 (DC-853) Dose 1, LY4100511 (DC-853) Dose 2, LY4100511 (DC-853) Dose 3, Midazolam, Repaglinide, Digoxin, Rosuvastatin
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Single Dose PK

NCT04200092
View directory record Official record
Conditions
Healthy
Interventions
0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo
Combination Product · Drug · Other
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 5, 2026, 3:02 AM EDT
Completed Not applicable Interventional

Medication Empowerment and Deprescription for Safety (MEDS) Study

NCT04612166
View directory record Official record
Conditions
Aging, Fall Injury
Interventions
Medication Action Plan and Patient Empowerment (MAP-PE )
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
60 Years to 110 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Clive, Iowa
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 5, 2026, 3:02 AM EDT